198 related articles for article (PubMed ID: 23059018)
1. Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
Perlis RH; Uher R; Perroud N; Fava M
J Clin Psychiatry; 2012 Nov; 73(11):1439-42. PubMed ID: 23059018
[TBL] [Abstract][Full Text] [Related]
2. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
[TBL] [Abstract][Full Text] [Related]
3. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
[TBL] [Abstract][Full Text] [Related]
4. Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort.
Davis LL; Rush JA; Wisniewski SR; Rice K; Cassano P; Jewell ME; Biggs MM; Shores-Wilson K; Balasubramani GK; Husain MM; Quitkin FM; McGrath PJ
Compr Psychiatry; 2005; 46(2):81-9. PubMed ID: 15723023
[TBL] [Abstract][Full Text] [Related]
5. SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
Grunebaum MF; Keilp JG; Ellis SP; Sudol K; Bauer N; Burke AK; Oquendo MA; Mann JJ
J Clin Psychiatry; 2013 Sep; 74(9):872-9. PubMed ID: 24107760
[TBL] [Abstract][Full Text] [Related]
6. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
[TBL] [Abstract][Full Text] [Related]
7. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
Thase ME; Friedman ES; Biggs MM; Wisniewski SR; Trivedi MH; Luther JF; Fava M; Nierenberg AA; McGrath PJ; Warden D; Niederehe G; Hollon SD; Rush AJ
Am J Psychiatry; 2007 May; 164(5):739-52. PubMed ID: 17475733
[TBL] [Abstract][Full Text] [Related]
8. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.
Katz AJ; Dusetzina SB; Farley JF; Ellis AR; Gaynes BN; Castillo WC; Stürmer T; Hansen RA
Pharmacotherapy; 2012 Mar; 32(3):234-43. PubMed ID: 22392456
[TBL] [Abstract][Full Text] [Related]
9. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
[TBL] [Abstract][Full Text] [Related]
10. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
Bech P; Fava M; Trivedi MH; Wisniewski SR; Rush AJ
Acta Psychiatr Scand; 2012 Apr; 125(4):342-8. PubMed ID: 22077211
[TBL] [Abstract][Full Text] [Related]
11. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Coughlin CG; Jakubovski E; Bloch MH
J Clin Psychiatry; 2016 Oct; 77(10):e1262-e1269. PubMed ID: 27631142
[TBL] [Abstract][Full Text] [Related]
12. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
Perlis RH; Purcell S; Fava M; Fagerness J; Rush AJ; Trivedi MH; Smoller JW
Arch Gen Psychiatry; 2007 Jun; 64(6):689-97. PubMed ID: 17548750
[TBL] [Abstract][Full Text] [Related]
13. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Brent DA
Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
[No Abstract] [Full Text] [Related]
14. The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
De La Garza N; Rush AJ; Killian MO; Grannemann BD; Carmody TJ; Trivedi MH
Depress Anxiety; 2019 Apr; 36(4):313-320. PubMed ID: 30370613
[TBL] [Abstract][Full Text] [Related]
15. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
Nierenberg AA; Husain MM; Trivedi MH; Fava M; Warden D; Wisniewski SR; Miyahara S; Rush AJ
Psychol Med; 2010 Jan; 40(1):41-50. PubMed ID: 19460188
[TBL] [Abstract][Full Text] [Related]
16. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
[TBL] [Abstract][Full Text] [Related]
17. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
Gaynes BN; Farley JF; Dusetzina SB; Ellis AR; Hansen RA; Miller WC; Stürmer T
Depress Anxiety; 2011 Nov; 28(11):989-98. PubMed ID: 21898717
[TBL] [Abstract][Full Text] [Related]
18. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Brent DA; Emslie GJ; Clarke GN; Asarnow J; Spirito A; Ritz L; Vitiello B; Iyengar S; Birmaher B; Ryan ND; Zelazny J; Onorato M; Kennard B; Mayes TL; Debar LL; McCracken JT; Strober M; Suddath R; Leonard H; Porta G; Keller MB
Am J Psychiatry; 2009 Apr; 166(4):418-26. PubMed ID: 19223438
[TBL] [Abstract][Full Text] [Related]
19. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
Trials; 2011 Jan; 12():4. PubMed ID: 21208417
[TBL] [Abstract][Full Text] [Related]
20. Medication augmentation after the failure of SSRIs for depression.
Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
